ALLO - Company ID 0001737287
The table below shows Allogene Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $32.00M | $31.16M | $40.16M | $50.20M | $44.71M | $50.35M |
Allogene Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $22.00K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $14.09M |
| $13.74M |
| $14.28M |
| $14.99M |
| $16.33M |
| $16.09M |
| Operating income | -$46.09M | -$44.90M | -$56.82M | -$65.19M | -$71.77M | -$71.43M |
| Income tax | - | - | - | - | - | - |
| Net income | -$42.61M | -$41.40M | -$50.94M | -$59.73M | -$66.29M | -$66.36M |
| EPS (diluted) | -$0.18 | -$0.19 | -$0.23 | -$0.28 | -$0.32 | -$0.35 |